REFERENCES
- Beauchamp, T. L., and J. F. Childress. 2013. Principles of biomedical ethics. New York, NY: Oxford University Press.
- Drug Watch. 2014. Actos and bladder cancer Available at: http://www.drugwatch.com/actos/bladder-cancer.php (accessed July 3, 2014).
- Food and Drug Administration. 2013. FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available at: http://www.fda.gov/drugs/drugsafety/ucm343187.htm (accessed July 3, 2014).
- Gallin, J. I., and F. P. Ognibene. 2012. Principles and practice of clinical research, 3rd ed. Waltham, MA: Elsevier Academic Press.
- Vernillo, A. 2009. Disclosure of adverse clinical trial results—Should legal immunity be granted to drug companies? American Journal of Bioethics 9(8): 45–47.
- Walker, M. J., W. A. Rogers, and V. Entwistle. 2014. Ethical justifications for access to unapproved medical interventions: An argument for (limited) patient obligations. American Journal of Bioethics 14(11): XX–XX.